Share Price and Basic Stock Data
Last Updated: January 17, 2026, 6:44 am
| PEG Ratio | 0.53 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dishman Carbogen Amcis Ltd operates within the pharmaceuticals sector, focusing on contract research and manufacturing services. The company’s reported sales for the fiscal year ending March 2025 stood at ₹2,712 Cr, reflecting a steady increase from ₹2,413 Cr in the previous fiscal year. The trailing twelve months (TTM) revenue reached ₹2,759 Cr, indicating consistent growth. Notably, quarterly sales exhibited fluctuations, with the highest quarterly revenue of ₹789 Cr recorded in September 2024, while the lowest was ₹524 Cr in June 2024. This variability suggests a response to market demands and operational adjustments. Furthermore, the company’s operating profit margin (OPM) has shown resilience, rising to 23% in the latest reporting period, showcasing effective cost management. Overall, the revenue trajectory suggests a robust demand for Dishman’s services, although the quarterly sales volatility highlights the need for strategic planning to stabilize income streams.
Profitability and Efficiency Metrics
Profitability metrics for Dishman Carbogen Amcis Ltd reveal a challenging landscape, with the latest net profit recorded at ₹3 Cr for the fiscal year ending March 2025, a notable recovery from a loss of ₹30 Cr in the previous year. The earnings per share (EPS) improved to ₹0.21, compared to a loss of ₹1.90 in the fiscal year 2023. However, the return on equity (ROE) stood at a modest 0.05%, indicating limited profitability relative to shareholders’ equity. The company reported an interest coverage ratio of 3.08x, suggesting a manageable level of debt, although a declining trend in operating profit margin from 21% to 17% in the past year raises concerns about operational efficiency. Additionally, the cash conversion cycle (CCC) lengthened to 577 days, indicating potential inefficiencies in inventory and receivables management. These profitability challenges underscore the necessity for Dishman to enhance its operational strategies while maintaining a focus on cost control.
Balance Sheet Strength and Financial Ratios
Dishman Carbogen Amcis Ltd’s balance sheet reflects a mixed financial position, with total assets reported at ₹9,987 Cr and total borrowings amounting to ₹2,559 Cr, resulting in a debt-to-equity ratio of 0.35x. This relatively conservative leverage indicates a robust capital structure. The company’s reserves grew to ₹6,334 Cr, affirming its financial cushion for future investments. The price-to-book value (P/BV) ratio was recorded at 0.58x, suggesting the stock may be undervalued compared to its book value, which stood at ₹371.91 per share. However, the return on capital employed (ROCE) remained low at 2.43%, highlighting inefficiencies in utilizing capital for generating profits. Additionally, the current ratio of 1.14x indicates adequate liquidity, while the quick ratio of 0.67x suggests potential challenges in meeting short-term obligations. These factors collectively present a stable yet cautious outlook for the company’s financial health.
Shareholding Pattern and Investor Confidence
The shareholding structure of Dishman Carbogen Amcis Ltd reveals significant promoter confidence, with promoters holding 59.32% of the equity. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), account for 8.07% and 1.37% of the shareholding, respectively. This distribution indicates a stable ownership base, although the relatively low institutional investment might suggest a degree of caution among larger investors. The number of shareholders reported at 49,455 indicates a diverse retail investor base, which can enhance liquidity. However, a decline in the number of shareholders from 61,175 in December 2022 to the current figure raises concerns about investor sentiment. As the company navigates profitability challenges, maintaining investor confidence will be crucial for future capital raising efforts and stock performance.
Outlook, Risks, and Final Insight
The outlook for Dishman Carbogen Amcis Ltd hinges on its ability to stabilize revenue amid fluctuating quarterly sales and enhance profitability in a competitive pharmaceutical landscape. Key strengths include a solid reserve position of ₹6,334 Cr and a manageable debt level, which provide a buffer for navigating market challenges. However, risks include the prolonged cash conversion cycle of 577 days, which could impact liquidity and operational efficiency, alongside low ROE and ROCE metrics that raise questions about capital utilization. Furthermore, the company’s dependency on contract manufacturing may expose it to market volatility. To enhance its market position, Dishman must focus on operational efficiencies and diversifying its service offerings, ensuring sustainable growth in an evolving industry. A proactive approach to investor relations and transparent communication will also be vital in bolstering investor confidence moving forward.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 207/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,910 Cr. | 356 | 479/192 | 81.0 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,989.74 Cr | 1,116.46 | 52.28 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 614 | 640 | 619 | 723 | 587 | 651 | 655 | 524 | 789 | 682 | 716 | 708 | 653 |
| Expenses | 535 | 526 | 567 | 602 | 526 | 610 | 592 | 495 | 642 | 542 | 564 | 567 | 504 |
| Operating Profit | 79 | 114 | 51 | 122 | 61 | 41 | 63 | 29 | 147 | 140 | 153 | 141 | 149 |
| OPM % | 13% | 18% | 8% | 17% | 10% | 6% | 10% | 6% | 19% | 21% | 21% | 20% | 23% |
| Other Income | 9 | 4 | -39 | 7 | 5 | 6 | 4 | -4 | 4 | 8 | -4 | 22 | 8 |
| Interest | 20 | 22 | 24 | 28 | 27 | 33 | 31 | 32 | 37 | 49 | 42 | 43 | 42 |
| Depreciation | 80 | 50 | 76 | 70 | 75 | 80 | 85 | 71 | 72 | 72 | 79 | 81 | 84 |
| Profit before tax | -12 | 46 | -88 | 29 | -36 | -66 | -49 | -78 | 42 | 27 | 28 | 39 | 31 |
| Tax % | -18% | -3% | -19% | 42% | 13% | -10% | 42% | 0% | 21% | 83% | -56% | 39% | -114% |
| Net Profit | -10 | 47 | -71 | 17 | -41 | -60 | -70 | -78 | 33 | 5 | 43 | 23 | 65 |
| EPS in Rs | -0.64 | 3.00 | -4.51 | 1.08 | -2.61 | -3.80 | -4.46 | -4.95 | 2.11 | 0.30 | 2.75 | 1.49 | 4.16 |
Last Updated: January 1, 2026, 10:34 pm
Below is a detailed analysis of the quarterly data for Dishman Carbogen Amcis Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 653.00 Cr.. The value appears to be declining and may need further review. It has decreased from 708.00 Cr. (Jun 2025) to 653.00 Cr., marking a decrease of 55.00 Cr..
- For Expenses, as of Sep 2025, the value is 504.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 567.00 Cr. (Jun 2025) to 504.00 Cr., marking a decrease of 63.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 149.00 Cr.. The value appears strong and on an upward trend. It has increased from 141.00 Cr. (Jun 2025) to 149.00 Cr., marking an increase of 8.00 Cr..
- For OPM %, as of Sep 2025, the value is 23.00%. The value appears strong and on an upward trend. It has increased from 20.00% (Jun 2025) to 23.00%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is 8.00 Cr.. The value appears to be declining and may need further review. It has decreased from 22.00 Cr. (Jun 2025) to 8.00 Cr., marking a decrease of 14.00 Cr..
- For Interest, as of Sep 2025, the value is 42.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 43.00 Cr. (Jun 2025) to 42.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 84.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 81.00 Cr. (Jun 2025) to 84.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 31.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Jun 2025) to 31.00 Cr., marking a decrease of 8.00 Cr..
- For Tax %, as of Sep 2025, the value is -114.00%. The value appears to be improving (decreasing) as expected. It has decreased from 39.00% (Jun 2025) to -114.00%, marking a decrease of 153.00%.
- For Net Profit, as of Sep 2025, the value is 65.00 Cr.. The value appears strong and on an upward trend. It has increased from 23.00 Cr. (Jun 2025) to 65.00 Cr., marking an increase of 42.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 4.16. The value appears strong and on an upward trend. It has increased from 1.49 (Jun 2025) to 4.16, marking an increase of 2.67.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:26 am
| Metric | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,031 | 1,714 | 1,695 | 2,059 | 2,044 | 1,912 | 2,141 | 2,413 | 2,616 | 2,712 | 2,759 |
| Expenses | 830 | 1,261 | 1,249 | 1,507 | 1,540 | 1,638 | 1,809 | 2,081 | 2,329 | 2,243 | 2,177 |
| Operating Profit | 201 | 452 | 445 | 552 | 503 | 274 | 331 | 332 | 286 | 469 | 582 |
| OPM % | 20% | 26% | 26% | 27% | 25% | 14% | 15% | 14% | 11% | 17% | 21% |
| Other Income | 14 | 26 | 46 | 54 | 39 | 16 | 29 | -20 | 22 | 4 | 34 |
| Interest | 56 | 49 | 49 | 57 | 62 | 48 | 57 | 86 | 120 | 159 | 176 |
| Depreciation | 69 | 214 | 211 | 240 | 283 | 308 | 308 | 281 | 311 | 294 | 317 |
| Profit before tax | 91 | 216 | 231 | 309 | 197 | -65 | -4 | -55 | -122 | 19 | 124 |
| Tax % | 12% | 33% | 33% | 32% | 20% | 154% | -524% | -45% | 26% | 83% | |
| Net Profit | 80 | 145 | 155 | 210 | 159 | -165 | 18 | -30 | -153 | 3 | 136 |
| EPS in Rs | 9.58 | 13.03 | 10.10 | -10.53 | 1.15 | -1.90 | -9.79 | 0.21 | 8.70 | ||
| Dividend Payout % | 0% | 0% | 0% | 2% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 6.90% | 35.48% | -24.29% | -203.77% | 110.91% | -266.67% | -410.00% | 101.96% |
| Change in YoY Net Profit Growth (%) | 0.00% | 28.59% | -59.77% | -179.49% | 314.68% | -377.58% | -143.33% | 511.96% |
Dishman Carbogen Amcis Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 8% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 150% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 31% |
| 1 Year: | 28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -1% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 3:05 am
Balance Sheet
Last Updated: December 10, 2025, 2:36 am
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 0.00 | 32 | 32 | 31 | 31 | 31 | 31 | 31 | 31 | 31 |
| Reserves | 863 | 4,814 | 5,075 | 5,347 | 5,684 | 5,667 | 5,518 | 5,778 | 5,596 | 5,800 | 6,334 |
| Borrowings | 868 | 950 | 1,095 | 1,042 | 1,357 | 1,589 | 1,830 | 2,209 | 2,313 | 2,389 | 2,559 |
| Other Liabilities | 334 | 811 | 967 | 899 | 1,121 | 1,068 | 1,255 | 1,421 | 1,631 | 1,766 | 2,185 |
| Total Liabilities | 2,081 | 6,574 | 7,169 | 7,321 | 8,193 | 8,356 | 8,634 | 9,439 | 9,571 | 9,987 | 11,109 |
| Fixed Assets | 1,012 | 4,852 | 5,066 | 5,098 | 5,678 | 5,698 | 5,773 | 6,188 | 6,724 | 7,055 | 7,954 |
| CWIP | 307 | 133 | 151 | 175 | 234 | 486 | 780 | 1,043 | 646 | 467 | 309 |
| Investments | 1 | 40 | 196 | 167 | 191 | 172 | 324 | 249 | 102 | 97 | 91 |
| Other Assets | 761 | 1,550 | 1,757 | 1,881 | 2,091 | 2,000 | 1,758 | 1,959 | 2,098 | 2,368 | 2,756 |
| Total Assets | 2,081 | 6,574 | 7,169 | 7,321 | 8,193 | 8,356 | 8,634 | 9,439 | 9,571 | 9,987 | 11,109 |
Below is a detailed analysis of the balance sheet data for Dishman Carbogen Amcis Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 31.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 31.00 Cr..
- For Reserves, as of Sep 2025, the value is 6,334.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,800.00 Cr. (Mar 2025) to 6,334.00 Cr., marking an increase of 534.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,559.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,389.00 Cr. (Mar 2025) to 2,559.00 Cr., marking an increase of 170.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,185.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,766.00 Cr. (Mar 2025) to 2,185.00 Cr., marking an increase of 419.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 11,109.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9,987.00 Cr. (Mar 2025) to 11,109.00 Cr., marking an increase of 1,122.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 7,954.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,055.00 Cr. (Mar 2025) to 7,954.00 Cr., marking an increase of 899.00 Cr..
- For CWIP, as of Sep 2025, the value is 309.00 Cr.. The value appears to be declining and may need further review. It has decreased from 467.00 Cr. (Mar 2025) to 309.00 Cr., marking a decrease of 158.00 Cr..
- For Investments, as of Sep 2025, the value is 91.00 Cr.. The value appears to be declining and may need further review. It has decreased from 97.00 Cr. (Mar 2025) to 91.00 Cr., marking a decrease of 6.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,756.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,368.00 Cr. (Mar 2025) to 2,756.00 Cr., marking an increase of 388.00 Cr..
- For Total Assets, as of Sep 2025, the value is 11,109.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,987.00 Cr. (Mar 2025) to 11,109.00 Cr., marking an increase of 1,122.00 Cr..
Notably, the Reserves (6,334.00 Cr.) exceed the Borrowings (2,559.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -667.00 | -498.00 | 444.00 | 551.00 | 502.00 | 273.00 | 330.00 | 330.00 | 284.00 | 467.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 60 | 61 | 96 | 79 | 103 | 80 | 81 | 89 | 68 | 90 |
| Inventory Days | 272 | 473 | 525 | 496 | 462 | 402 | 526 | 568 | 540 | 655 |
| Days Payable | 172 | 95 | 201 | 176 | 226 | 132 | 158 | 155 | 149 | 168 |
| Cash Conversion Cycle | 160 | 439 | 419 | 399 | 340 | 350 | 449 | 502 | 458 | 577 |
| Working Capital Days | -52 | 35 | 44 | 43 | -10 | -2 | -8 | -37 | -148 | -35 |
| ROCE % | 5% | 6% | 4% | 0% | 1% | 1% | 0% | 2% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HSBC Flexi Cap Fund | 1,476,000 | 0.67 | 35.31 | 2,377,050 | 2025-12-07 05:28:48 | -37.91% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 0.21 | -9.79 | -1.90 | 1.15 | -10.53 |
| Diluted EPS (Rs.) | 0.21 | -9.79 | -1.90 | 1.15 | -10.53 |
| Cash EPS (Rs.) | 18.94 | 10.04 | 16.00 | 20.77 | 9.11 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 371.91 | 358.90 | 370.51 | 353.89 | 363.44 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 371.91 | 358.90 | 370.51 | 353.89 | 363.44 |
| Revenue From Operations / Share (Rs.) | 172.93 | 166.82 | 153.89 | 136.52 | 121.94 |
| PBDIT / Share (Rs.) | 31.29 | 20.07 | 22.96 | 23.90 | 19.95 |
| PBIT / Share (Rs.) | 12.56 | 0.24 | 5.05 | 4.29 | 0.30 |
| PBT / Share (Rs.) | 1.23 | -7.80 | -3.48 | -0.27 | -4.15 |
| Net Profit / Share (Rs.) | 0.20 | -9.79 | -1.90 | 1.15 | -10.53 |
| NP After MI And SOA / Share (Rs.) | 0.20 | -9.79 | -1.90 | 1.15 | -10.53 |
| PBDIT Margin (%) | 18.09 | 12.03 | 14.91 | 17.50 | 16.35 |
| PBIT Margin (%) | 7.26 | 0.14 | 3.28 | 3.13 | 0.25 |
| PBT Margin (%) | 0.71 | -4.67 | -2.26 | -0.19 | -3.40 |
| Net Profit Margin (%) | 0.11 | -5.86 | -1.23 | 0.84 | -8.63 |
| NP After MI And SOA Margin (%) | 0.11 | -5.86 | -1.23 | 0.84 | -8.63 |
| Return on Networth / Equity (%) | 0.05 | -2.72 | -0.51 | 0.32 | -2.89 |
| Return on Capital Employeed (%) | 2.43 | 0.05 | 1.03 | 0.93 | 0.06 |
| Return On Assets (%) | 0.03 | -1.60 | -0.31 | 0.20 | -1.98 |
| Long Term Debt / Equity (X) | 0.19 | 0.04 | 0.18 | 0.13 | 0.08 |
| Total Debt / Equity (X) | 0.35 | 0.34 | 0.31 | 0.25 | 0.18 |
| Asset Turnover Ratio (%) | 0.27 | 0.27 | 0.26 | 0.04 | 0.03 |
| Current Ratio (X) | 1.14 | 0.75 | 1.07 | 1.29 | 1.33 |
| Quick Ratio (X) | 0.67 | 0.40 | 0.61 | 0.84 | 0.91 |
| Inventory Turnover Ratio (X) | 3.04 | 0.71 | 0.86 | 0.29 | 0.22 |
| Interest Coverage Ratio (X) | 3.08 | 2.62 | 4.20 | 6.60 | 6.57 |
| Interest Coverage Ratio (Post Tax) (X) | 1.13 | -0.22 | 1.21 | 1.57 | -2.00 |
| Enterprise Value (Cr.) | 4988.85 | 5245.26 | 3590.64 | 4151.85 | 2477.79 |
| EV / Net Operating Revenue (X) | 1.84 | 2.01 | 1.49 | 1.94 | 1.30 |
| EV / EBITDA (X) | 10.17 | 16.67 | 9.97 | 11.08 | 7.92 |
| MarketCap / Net Operating Revenue (X) | 1.26 | 1.41 | 0.81 | 1.36 | 0.89 |
| Price / BV (X) | 0.58 | 0.65 | 0.33 | 0.52 | 0.29 |
| Price / Net Operating Revenue (X) | 1.26 | 1.41 | 0.81 | 1.36 | 0.89 |
| EarningsYield | 0.00 | -0.04 | -0.01 | 0.01 | -0.09 |
After reviewing the key financial ratios for Dishman Carbogen Amcis Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.21. This value is below the healthy minimum of 5. It has increased from -9.79 (Mar 24) to 0.21, marking an increase of 10.00.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.21. This value is below the healthy minimum of 5. It has increased from -9.79 (Mar 24) to 0.21, marking an increase of 10.00.
- For Cash EPS (Rs.), as of Mar 25, the value is 18.94. This value is within the healthy range. It has increased from 10.04 (Mar 24) to 18.94, marking an increase of 8.90.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 371.91. It has increased from 358.90 (Mar 24) to 371.91, marking an increase of 13.01.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 371.91. It has increased from 358.90 (Mar 24) to 371.91, marking an increase of 13.01.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 172.93. It has increased from 166.82 (Mar 24) to 172.93, marking an increase of 6.11.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 31.29. This value is within the healthy range. It has increased from 20.07 (Mar 24) to 31.29, marking an increase of 11.22.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.56. This value is within the healthy range. It has increased from 0.24 (Mar 24) to 12.56, marking an increase of 12.32.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.23. This value is within the healthy range. It has increased from -7.80 (Mar 24) to 1.23, marking an increase of 9.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 2. It has increased from -9.79 (Mar 24) to 0.20, marking an increase of 9.99.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 2. It has increased from -9.79 (Mar 24) to 0.20, marking an increase of 9.99.
- For PBDIT Margin (%), as of Mar 25, the value is 18.09. This value is within the healthy range. It has increased from 12.03 (Mar 24) to 18.09, marking an increase of 6.06.
- For PBIT Margin (%), as of Mar 25, the value is 7.26. This value is below the healthy minimum of 10. It has increased from 0.14 (Mar 24) to 7.26, marking an increase of 7.12.
- For PBT Margin (%), as of Mar 25, the value is 0.71. This value is below the healthy minimum of 10. It has increased from -4.67 (Mar 24) to 0.71, marking an increase of 5.38.
- For Net Profit Margin (%), as of Mar 25, the value is 0.11. This value is below the healthy minimum of 5. It has increased from -5.86 (Mar 24) to 0.11, marking an increase of 5.97.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.11. This value is below the healthy minimum of 8. It has increased from -5.86 (Mar 24) to 0.11, marking an increase of 5.97.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 15. It has increased from -2.72 (Mar 24) to 0.05, marking an increase of 2.77.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.43. This value is below the healthy minimum of 10. It has increased from 0.05 (Mar 24) to 2.43, marking an increase of 2.38.
- For Return On Assets (%), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from -1.60 (Mar 24) to 0.03, marking an increase of 1.63.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 0.2. It has increased from 0.04 (Mar 24) to 0.19, marking an increase of 0.15.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.35. This value is within the healthy range. It has increased from 0.34 (Mar 24) to 0.35, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.27. There is no change compared to the previous period (Mar 24) which recorded 0.27.
- For Current Ratio (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 1.5. It has increased from 0.75 (Mar 24) to 1.14, marking an increase of 0.39.
- For Quick Ratio (X), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 1. It has increased from 0.40 (Mar 24) to 0.67, marking an increase of 0.27.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.04. This value is below the healthy minimum of 4. It has increased from 0.71 (Mar 24) to 3.04, marking an increase of 2.33.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.08. This value is within the healthy range. It has increased from 2.62 (Mar 24) to 3.08, marking an increase of 0.46.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 3. It has increased from -0.22 (Mar 24) to 1.13, marking an increase of 1.35.
- For Enterprise Value (Cr.), as of Mar 25, the value is 4,988.85. It has decreased from 5,245.26 (Mar 24) to 4,988.85, marking a decrease of 256.41.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.84. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.84, marking a decrease of 0.17.
- For EV / EBITDA (X), as of Mar 25, the value is 10.17. This value is within the healthy range. It has decreased from 16.67 (Mar 24) to 10.17, marking a decrease of 6.50.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.26. This value is within the healthy range. It has decreased from 1.41 (Mar 24) to 1.26, marking a decrease of 0.15.
- For Price / BV (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has decreased from 0.65 (Mar 24) to 0.58, marking a decrease of 0.07.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.26. This value is within the healthy range. It has decreased from 1.41 (Mar 24) to 1.26, marking a decrease of 0.15.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.04 (Mar 24) to 0.00, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dishman Carbogen Amcis Ltd:
- Net Profit Margin: 0.11%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.43% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.05% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.13
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.67
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 26.6 (Industry average Stock P/E: 52.28)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.35
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.11%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Dishman Corporate House, Ahmedabad Gujarat 380058 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Arpit J Vyas | Managing Director |
| Mrs. Deohooti J Vyas | Whole Time Director |
| Mr. Kulin N Shah | Director |
| Mr. Hemantkumar J Bhatt | Director |
| Dr. Margie S Parikh | Director |
| Mr. Maitri K Mehta | Independent Director |
| Mr. Rajendra S Shah | Independent Director |
| Mr. Dhaval R Shah | Additional Director |
FAQ
What is the intrinsic value of Dishman Carbogen Amcis Ltd?
Dishman Carbogen Amcis Ltd's intrinsic value (as of 17 January 2026) is ₹42.27 which is 83.36% lower the current market price of ₹254.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,984 Cr. market cap, FY2025-2026 high/low of ₹322/178, reserves of ₹6,334 Cr, and liabilities of ₹11,109 Cr.
What is the Market Cap of Dishman Carbogen Amcis Ltd?
The Market Cap of Dishman Carbogen Amcis Ltd is 3,984 Cr..
What is the current Stock Price of Dishman Carbogen Amcis Ltd as on 17 January 2026?
The current stock price of Dishman Carbogen Amcis Ltd as on 17 January 2026 is ₹254.
What is the High / Low of Dishman Carbogen Amcis Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dishman Carbogen Amcis Ltd stocks is ₹322/178.
What is the Stock P/E of Dishman Carbogen Amcis Ltd?
The Stock P/E of Dishman Carbogen Amcis Ltd is 26.6.
What is the Book Value of Dishman Carbogen Amcis Ltd?
The Book Value of Dishman Carbogen Amcis Ltd is 406.
What is the Dividend Yield of Dishman Carbogen Amcis Ltd?
The Dividend Yield of Dishman Carbogen Amcis Ltd is 0.00 %.
What is the ROCE of Dishman Carbogen Amcis Ltd?
The ROCE of Dishman Carbogen Amcis Ltd is 2.42 %.
What is the ROE of Dishman Carbogen Amcis Ltd?
The ROE of Dishman Carbogen Amcis Ltd is 0.32 %.
What is the Face Value of Dishman Carbogen Amcis Ltd?
The Face Value of Dishman Carbogen Amcis Ltd is 2.00.